Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue while reporting ...

Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a ...

One positive sign was that Vertex raised the lower end of its forecast for full-year 2025 revenue by $100 million. The ...